Residual Adrenal Function in Addison's Disease

NCT ID: NCT06309498

Last Updated: 2024-03-13

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 50 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2023-01-01
• Study Completion Date: 2024-12-31

Brief Summary

The main aim of this study is to assess the role of 11-deoxycortisol as surrogate marker of Residual adrenal function.

11-deoxycortisol levels will be assessed in all recruited patients

Detailed Description

Addison's disease is an autoimmune disease characterized by inadequate secretion of cortisol and aldosteron by adrenal cortex as a consequence of progressive destruction of the adrenal gland. The absence of specific signs and symptoms could delay the diagnosis and treatment. Considering the importance of these two hormones, a not adequate treatment can result in Addisonian crisis and even be a cause of increased mortality.

Actually, diagnosis is based either on low basal cortisol levels or cortisol levels after Synacthen test (250 mcg) < 500 nmol/L.

Adrenal insufficiency (AI) is most of the time the inevitable end result of the autoimmune process, but some cases of partial recovery of adrenal function in a patient with autoimmune Addison's disease have been described.

Recent evidence shows that 5-30% of Addison's patients, also after many years of disease, maintain a residual endogenous corticosteroid production thanks to a partial adrenal cortex functionality, known as residual adrenal function (RAF).

Indeed, some studies show how the 3-15% of patients have detectable cortisol at Synacthen 250 mcg test, demonstrating that in one third of patients with long-standing disease, some RAF was still present.

The clinical significance of this RAF is unknown but potentially can reduce the need of hormone replacement, affecting the patient's quality of life. An approach to determine residual endogenous cortisol production may be the measurement of its precursor, 11-deoxycortisol (11DOC).

The main aim of this study is to assess the role of 11DOC as surrogate marker of RAF.

It is expected that 15% of our population have a RAF. In patients with RAF we expect significantly higher 11DOC values and at the same time a lower prevalence of Addisonian crisis with a higher prevalence of complications as diabetes mellitus, arterial hypertension, osteoporosis and infections caused by the overtreatment.

Meanwhile, in patients without RAF a higher rate of Addisonian crisis despite a higher dose of treatment is expected.

The possibility to map the RAF in patients on hydrocortisone substitutive therapy by the use of a single marker (11DOC) could be useful as it permits to have a more patient- based medical approach without having to carry out time consuming tests (e.g.Synacthen Test).

Despite the pharmacological approach actually Addison's patients have an impaired quality of life. For the AI treatment in adults, the Endocrine European Society's recommended daily glucocorticoid replacement dose (DGRD) is 15 to 25 mg hydrocortisone. Under-replacement may result in weight loss, hypotension, hyponatremia, and death. In contrast, glucocorticoids excess may cause metabolic complications and immune suppression.

If this hypothesis were confirmed it could be helpful to reduce the DGRD in patients with RAF, in order to minimize the incidence of complication of long-term therapy. On the other side, in patients without RAF, it could be useful to take more attention to reduce the risk of Addisonian's crisis.

Last but not least, finding a marker of RAF, as 11DOC, without having to perform further tests, could allow to reduce timing and costs for the single Addison's patient evaluation.

Conditions

Adrenal Insufficiency

Study Design

• Observational Model Type: CASE_ONLY
• Study Time Perspective: CROSS_SECTIONAL

Interventions

blood test

11 DOC levels will be measured in enrolled patients

Intervention Type: PROCEDURE

Other Intervention Names

11 DOC measurement

Eligibility Criteria

Inclusion Criteria

• Autoimmune Addison's disease
• Informed consent

Exclusion Criteria

• Drugs affecting immune system or steroids other than hydrocortisone or cortisone acetate

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Istituto Auxologico Italiano

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Valentina Morelli, PHD

Role: PRINCIPAL_INVESTIGATOR

Istituto Auxologico Italiano

Locations

Istituto Auxologico Italiano

Milan, , Italy

Site Status: RECRUITING

Countries

Italy

Central Contacts

Valentina Morelli, PhD

Role: CONTACT

v.morelli@auxologico.it

02619112547

Carmen Aresta, MD

Role: CONTACT

c.aresta@auxologico.it

02619112547

Facility Contacts

Valentina Morelli

Role: primary

v.morelli@auxologico.it

02619112547

References

Pearce SHS, Gan EH, Napier C. MANAGEMENT OF ENDOCRINE DISEASE: Residual adrenal function in Addison's disease. Eur J Endocrinol. 2021 Feb;184(2):R61-R67. doi: 10.1530/EJE-20-0894.

Reference Type: BACKGROUND

PMID: 33306039 (View on PubMed)

Vulto A, Bergthorsdottir R, van Faassen M, Kema IP, Johannsson G, van Beek AP. Residual endogenous corticosteroid production in patients with adrenal insufficiency. Clin Endocrinol (Oxf). 2019 Sep;91(3):383-390. doi: 10.1111/cen.14006. Epub 2019 Jun 20.

Reference Type: BACKGROUND

PMID: 31059146 (View on PubMed)

Other Identifiers

05C307

Identifier Type: -

Identifier Source: org_study_id